Journal
BRAIN
Volume 140, Issue -, Pages 1399-1419Publisher
OXFORD UNIV PRESS
DOI: 10.1093/brain/awx056
Keywords
glycation; Parkinson's disease; neurodegeneration; alpha-synuclein
Categories
Funding
- Fundacao para a Ciencia e Tecnologia (FCT), Portugal [SFRH/BPD/64702/2009, SFRH/BPD/109347/2015, FCT SFRH/BPD/41416/2007, SFRH/BPD/31209/2006]
- EU FP7 project MEFOPA
- CIRM-BMFB [315050 AZ0101-31P6855]
- Deutsche Forschungsgemeinschaft [SFB539/A3]
- Israel Academy of Sciences
- Rappaport Family Institute for Research in the Medical Sciences
- Allen and Jewel Prince Center for Neurodegenerative Disorders of the Brain
- EU
- Max Planck Society
- European Union [NEURASYNC PITNGA-2009-238316]
- [FCT - SFRH/BD/23604/2005]
- [FCT SFRH/BPD/74287/2010]
- [Investigador FCT IF/00772/2013]
- [FCT PTDC/SAUNEU/105215/2008]
- [PTDC/QUI/73430/2006]
- [PTDC/SAU-ENB/117013/2010]
- [PTDC/NEU-OSD/5644/2014]
- Fundação para a Ciência e a Tecnologia [SFRH/BPD/31209/2006, PTDC/NEU-OSD/5644/2014, PTDC/SAU-ENB/117013/2010, PTDC/QUI/73430/2006, PTDC/SAU-NEU/105215/2008] Funding Source: FCT
- Parkinson's UK [G-1203] Funding Source: researchfish
Ask authors/readers for more resources
alpha-Synuclein misfolding and aggregation is a hallmark in Parkinson's disease and in several other neurodegenerative diseases known as synucleinopathies. The toxic properties of alpha-synuclein are conserved from yeast to man, but the precise underpinnings of the cellular pathologies associated are still elusive, complicating the development of effective therapeutic strategies. Combining molecular genetics with target-based approaches, we established that glycation, an unavoidable age-associated post-translational modification, enhanced alpha-synuclein toxicity in vitro and in vivo, in Drosophila and in mice. Glycation affected primarily the N-terminal region of alpha-synuclein, reducing membrane binding, impaired the clearance of alpha-synuclein, and promoted the accumulation of toxic oligomers that impaired neuronal synaptic transmission. Strikingly, using glycation inhibitors, we demonstrated that normal clearance of alpha-synuclein was re-established, aggregation was reduced, and motor phenotypes in Drosophila were alleviated. Altogether, our study demonstrates glycation constitutes a novel drug target that can be explored in synucleinopathies as well as in other neurodegenerative conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available